Pfizer-backed Mission raises £25.2m to progress clinical development of key drugs

Blue chip international investors have weighed into a £25.2 million fundraising round to back significant progress for Cambridge clinical stage biotech Mission Therapeutics. The company is developing first-in-class therapeutics that enhance mitophagy to promote cell/organ health.